닫기
18.97.9.172
18.97.9.172
close menu
Accredited SCIE SCOPUS
Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus
( Xin Li ) , ( Fengri Jin ) , ( Hyun Jae Lee ) , ( Choong Jae Lee )
UCI I410-ECN-0102-2021-500-001163403
* This article is free of use.

Hypersecretion of pulmonary mucus is a major pathophysiological feature in allergic and inflammatory respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Overproduction and/or oversecretion of mucus cause the airway obstruction and the colonization of pathogenic microbes. Developing a novel pharmacological agent to regulate the production and/or secretion of pulmonary mucus can be a useful strategy for the effective management of pathologic hypersecretion of mucus observed in COPD and asthma. Thus, in the present review, we tried to give an overview of the conventional pharmacotherapy for mucus-hypersecretory diseases and recent research results on searching for the novel candidate agents for controlling of pulmonary mucus hypersecretion, aiming to shed light on the potential efficacious pharmacotherapy of mucus-hypersecretory diseases.

INTRODUCTION
CONVENTIONAL PHARMACOTHERAPY FOR THE MANAGEMENT OF PULMONARY DISEASES SHOWING HYPERSECRETION OF MUCUS
THE NOVEL CANDIDATE AGENTS UNDER INVESTIGATION FOR REGULATING THE SECRETION OF PULMONARY MUCUS
CONFLICT OF INTEREST
ACKNOWLEDGMENTS
REFERENCES
[자료제공 : 네이버학술정보]
×